Barclays PLC Raises Stock Holdings in Enfusion, Inc. (NYSE:ENFN)

Barclays PLC increased its stake in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 251.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 86,039 shares of the company's stock after acquiring an additional 61,554 shares during the period. Barclays PLC owned about 0.07% of Enfusion worth $817,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of ENFN. Arizona State Retirement System acquired a new stake in shares of Enfusion during the 2nd quarter worth approximately $86,000. Harbor Capital Advisors Inc. grew its position in Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock valued at $113,000 after buying an additional 1,315 shares during the period. Belvedere Trading LLC purchased a new position in Enfusion in the third quarter valued at $114,000. Paloma Partners Management Co acquired a new position in shares of Enfusion in the third quarter worth about $157,000. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Enfusion by 27.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company's stock worth $167,000 after acquiring an additional 4,239 shares in the last quarter. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Enfusion news, CFO Bradley Herring sold 4,134 shares of Enfusion stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $41,877.42. Following the transaction, the chief financial officer now directly owns 266,369 shares of the company's stock, valued at $2,698,317.97. The trade was a 1.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Neal Pawar sold 21,801 shares of the business's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the transaction, the chief operating officer now owns 1,143,544 shares in the company, valued at $11,469,746.32. The trade was a 1.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 58,041 shares of company stock worth $597,367 over the last three months. Insiders own 36.44% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Stifel Nicolaus lifted their price target on Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. William Blair restated a "market perform" rating on shares of Enfusion in a research report on Monday. Finally, Piper Sandler increased their target price on Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a research report on Monday, December 23rd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $10.25.

Enfusion Stock Performance

Shares of ENFN traded up $0.04 during trading hours on Thursday, hitting $10.96. 2,004,366 shares of the stock were exchanged, compared to its average volume of 1,464,083. The stock's 50-day moving average price is $10.22 and its two-hundred day moving average price is $9.25. Enfusion, Inc. has a 12-month low of $7.52 and a 12-month high of $11.38. The company has a market cap of $1.41 billion, a price-to-earnings ratio of 273.69, a price-to-earnings-growth ratio of 1.58 and a beta of 0.95.

Enfusion Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.